Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

However, Infosys defended itself, stating that the terminated freshers failed to clear multiple internal tests that are part of the onboarding process. "All freshers get three attempts to clear ...

The Super Bowl LX logo has been leaked, and football fans believe they've discovered the script for the big game .

After hours: February 10 at 6:40:00 PM EST ...

For more control, third-party tools like TranslucentTB and TaskbarTools let users make the taskbar fully transparent or adjust its transparency level. These apps are easy to use, lightweight, and ...